U.S. flag

An official website of the United States government

NM_001134831.2(AHI1):c.*588A>G AND Joubert syndrome 3

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jan 13, 2018
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000376893.5

Allele description [Variation Report for NM_001134831.2(AHI1):c.*588A>G]

NM_001134831.2(AHI1):c.*588A>G

Gene:
AHI1:Abelson helper integration site 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
6q23.3
Genomic location:
Preferred name:
NM_001134831.2(AHI1):c.*588A>G
HGVS:
  • NC_000006.12:g.135285057T>C
  • NG_008643.2:g.217709A>G
  • NM_001134830.2:c.*588A>G
  • NM_001134831.2:c.*588A>GMANE SELECT
  • NM_001350503.2:c.*588A>G
  • NM_001350504.2:c.*569A>G
  • NM_017651.5:c.*588A>G
  • NC_000006.11:g.135606195T>C
  • NM_017651.4:c.*588A>G
Links:
dbSNP: rs555215397
NCBI 1000 Genomes Browser:
rs555215397
Molecular consequence:
  • NM_001134830.2:c.*588A>G - 3 prime UTR variant - [Sequence Ontology: SO:0001624]
  • NM_001134831.2:c.*588A>G - 3 prime UTR variant - [Sequence Ontology: SO:0001624]
  • NM_001350503.2:c.*588A>G - 3 prime UTR variant - [Sequence Ontology: SO:0001624]
  • NM_001350504.2:c.*569A>G - 3 prime UTR variant - [Sequence Ontology: SO:0001624]
  • NM_017651.5:c.*588A>G - 3 prime UTR variant - [Sequence Ontology: SO:0001624]

Condition(s)

Name:
Joubert syndrome 3 (JBTS3)
Synonyms:
Joubert syndrome with ocular anomalies; AHI1-related Ciliopathy
Identifiers:
MONDO: MONDO:0012078; MedGen: C1837713; Orphanet: 220493; OMIM: 608629

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV000460463Illumina Laboratory Services, Illumina
criteria provided, single submitter

(ICSL Variant Classification Criteria 13 December 2019)		Uncertain significance
(Jan 13, 2018) 		germlineclinical testing

Citation Link

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Illumina Laboratory Services, Illumina, SCV000460463.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 8, 2024